📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial. (2017)

First Author: Stark DP

Attributed to: MRC Clinical Trials Unit as the London Hub for Trials Methodology Research funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/cncr.30657

PubMed Identifier: 28339098

Publication URI: http://europepmc.org/abstract/MED/28339098

Type: Journal Article/Review

Volume: 123

Parent Publication: Cancer

Issue: 14

ISSN: 0008-543X